Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Lengyelország2. fázis

A multicentre study evaluating the safety of reperfusion thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtPA) for ischaemic stroke in patients on the non-vitamin K antagonist oral anticoagulant after reversing anticoagulant activity with a specific antidote.

A legfontosabb adatok

Ki végzi
Medical University Of Gdansk
Hol
Gdansk, Lodz, Rzeszów, Warsaw és Wroclaw (Lengyelország)Mind a 5 helyszín megnézése
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
215 fő, tervezett
Kezdés
2022. jan. 10.
Tervezett befejezés
2026. jún. 30.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. március 7.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek akut iszkémiás agyi érkatasztrófájuk (szélütésük) van, és apixabant vagy rivaroxabant (DOAC vérhígítót) szednek. A vizsgálat azt teszi próbára, hogy a vérrög-oldó rtPA kezelés biztonságos-e, miután a vérhígító hatását ellenszerrel megszüntették.

Életkor
18 évnél idősebb (a megfigyeléses részben: legalább 18 éves).
Nem
Minden nem részt vehet.
A betegség stádiuma
Akut iszkémiás szélütés, hirtelen kezdődő tünetekkel és mozgásképtelenséget okozó idegrendszeri kieséssel. A kiesés nem lehet túl súlyos (NIHSS legfeljebb 18 pont). A kezelés megkezdhető kell legyen a tünetek kezdetétől számított 4,5 órán belül, vagy 6,0 órán belül, ha egyértelmű klinikai ok miatt késett.
Korábbi kezelés
Apixabant vagy rivaroxabant kell szednie, és a vérszintje (anti-Xa aktivitás) 50 ng/mL fölött kell legyen. Az elmúlt 7 napban nem kaphatott más vérhígítót, teljes vért vagy alvadási faktort.
Biomarker vagy leletérték
Anti-Xa aktivitás 50 ng/mL fölött a vérben (ez mutatja, hogy a vérhígító még hat).

A részvétel fő kizáró okai

  • Nagy agyi ér elzáródása, ami mechanikus trombektómiát (rögeltávolítást) igényel
  • Agyi vérzés, vagy korábbi agyi vagy subarachnoidális vérzés
  • Súlyos mozgáskorlátozottság a szélütés előtt (mRS 2 pont fölött)
  • Nagyon súlyos szélütés (NIHSS 18 pont fölött), vagy enyhe, gyorsan javuló kiesés
  • Nagy műtét vagy sérülés az elmúlt 2 hónapban, vagy szívinfarktus az elmúlt 4 hétben

A regiszter feltételei, szó szerint

Mind a 4 feltétel megnézéseKevesebb

Ki vehet részt

  • INTERVENTIONAL PART OF THE STROACT STUDY: 1. Obtaining informed consent to participate in the trial. NOTE: Patients whose neurological deficit is severe enough to make it impossible to sign the consent form are allowed to give only their oral consent to participate in the study. However, this consent should be additionally certified by the signature of two independent witnesses (who are neither family members of the patient nor the STROACT study staff) or by the signature of his/her legal representative. Patients with aphasia and/or other speech disorders may be included into the study if following neurological assessment of the recruiting stroke physician, they are able to understand all important information about the study. 2. Age >18 years. 3. Clinical diagnosis of acute ischemic stroke (sharply defined onset of first symptoms) resulting in a disabling neurological deficit. 4. Therapy with an oral anticoagulant that is the non-vitamin K antagonist oral anticoagulant (apixaban or rivaroxaban) with laboratory confirmed therapeutic anti-Xa activity measured as a plasma concentration > 50 ng/mL. 5. Administration of study intervention (intravenous thrombolysis with alteplase) should be possible to start within 4.5 hours from AIS symptoms onset or the last time the patient was seen without symptoms, as per investigator’s judgment. NOTE: If a patient was enrolled and there was a clear clinical reason for delaying the start of the study intervention within the 4.5-hour window, the patient may still be included in the study if rtPA can be given within 6.0 hours of the onset of acute ischemic stroke. NOTE: In patients recruited to STROACT study, in addition to the inclusion / exclusion criteria, apply all standard clinical practice indications and contraindications for rtPA administration in acute ischemic stroke unless stated otherwise in this protocol
  • OBSERVATIONAL PART OF THE STROACT STUDY: 1. Age ≥ 18 years. 2. Clinical diagnosis of acute ischemic stroke (with sharply defined onset of first symptoms or last known well within 24 hours with laboratory confirmed therapeutic anti-IIa/Xa activity measured as a plasma concentration >50 ng/mL). 3. Therapy with an oral anticoagulant that is the non-vitamin K antagonist oral anticoagulant (dabigatran, apixaban or rivaroxaban) with laboratory confirmed therapeutic anti-IIa/Xa activity measured as a plasma concentration >50 ng/mL. 4. The neurological deficit rapidly improved to the point of a non-disabling deficit before obtaining the ICF to participate in the interventional part of the STROACT study. 5. Obtaining the ICF to participate in the observational part of the STROACT study

Ki nem vehet részt

  • INTERVENTIONAL PART OF THE STROACT STUDY: 1. Occlusion of a large intracranial vessel in CT/MR angiography (CTA/MRA), corresponding to the current acute neurological deficit being an indication for primary mechanical thrombectomy. 2. Significant disability prior to the current stroke event defined as >2 points on the modified Rankin Scale (mRS) and/or significant impairment of the cognitive function prior to AIS (the latter documented in patient’s medical records). 3. Mild and rapidly improving neurological deficit with high probability of complete recovery. 4. Clinically severe stroke with >18 points in NIHSS. 5. Neuroimaging findings that might be responsible for acute neurological deficit (“stroke mimics”) and/or are contraindications for standard thrombolytic treatment: such as intracranial and/or intracerebral bleeding, tumours, abscesses and other. 6. Treatment with the following anticoagulants: a. Oral vitamin K antagonist (warfarin, acenocumarol), b. Unfractionated heparin, c. Low molecular weight heparin, or d. Inhibitors of coagulation factor IIa (dabigatran) and Xa other than rivaroxaban or apixaban 7. Whole blood, and/or blood clotting factors (such as: prothrombin complex concentrate [PCC], recombinant factor VIIa [rVIIa], fresh frozen plasma [FFP]) administered within 7 days before study treatment initiation. 8. Anti-Xa activity (which is assumed to be directly proportional to the DOAC plasma concentration) is <50 ng/mL. 9. CT or MRI initial lesion volume >1/2 of the anatomical perfusion area of the middle cerebral artery (MCA), or anterior cerebral artery (ACA), or posterior cerebral artery (PCA). 10. Suspected subarachnoid haemorrhage based on specific symptomatology and/or physical examination (even if CT/MRI is normal). 11. Any history of subarachnoid or intracerebral haemorrhage, so not including previous (currently normal in neuroimaging) traumatic sub-or epidural hematomas > 6 months before the current acute stroke. 12. Any past (chronic) medical illnesses that significantly impair patient’s functional status down to mRS 3 points or more (thus not only related to CNS pathologies and including cognitive impairment), and/or with a poor prognosis (e.g., neoplasms individually assessed to be of poor prognosis). NOTE: Patients after treatment of intracranial aneurysm may be considered for recruitment into the STROACT trial if the procedure was performed > 3 months prior to enrollment. 13. History of major surgery / trauma within 2 months before the current acute stroke. 14. History of acute ischemic stroke or any other medical condition treated with intravenous thrombolysis, or ischemic stroke treated with mechanical thrombectomy, within the 72 hours preceding the current patient’s stroke symptoms. 15. Recent (within 10 preceding days) traumatic external heart massage, obstetrical delivery, lumbar puncture, any puncture of a non-compressible blood vessel. 16. Recent (within 4 preceding weeks) myocardial infarction. 17. Severe trauma at the onset of acute ischemic stroke (e.g., skull fracture, long bone fracture, pelvic fracture). 18. Expected need for major surgery within 72 hours after enrollment (e.g., laparotomy, hip femoral/pelvic fracture surgery, endarterectomy). 19.Cerebral venous sinus thrombosis (CVST). 20.Pulmonary embolism. 21.Suspected infective endocarditis and/or pericarditis. 22.Acute pancreatitis. 23.Systemic or suspected cerebral vasculitis
  • OBSERVATIONAL PART OF THE STROACT STUDY: 1.Occlusion of a large intracranial vessel in CT/MR angiography (CTA/MRA), corresponding to the current acute neurological deficit being an indication for primary mechanical thrombectomy. NOTE 1: Patients who qualified to the mechanical thrombectomy cannot be enrolled to the observational part of the STROACT study. 2. Significant disability prior to the current stroke event defined as >2 points on the modified Rankin Scale (mRS) and/or significant impairment of the cognitive function prior to AIS (the latter documented in patient’s medical records). 3. Neuroimaging findings that might be responsible for acute neurological deficit (“stroke mimics”). 4. Treatment with the following anticoagulants: a. Oral vitamin K antagonist (warfarin, acenocumarol), b. Unfractionated heparin, c. Low molecular weight heparin, or d. Inhibitors of coagulation factor IIa/Xa other than dabigatran, rivaroxaban or apixaban 5. Whole blood, and/or blood clotting factors (such as: prothrombin complex concentrate [PCC], recombinant factor VIIa [rVIIa], fresh frozen plasma [FFP]) administered within 7 days before enrollment to the study. 6. Anti-IIa/Xa activity (which is assumed to be directly proportional to the DOAC plasma concentration) is <50 ng/. 7. Suspected subarachnoid haemorrhage based on specific symptomatology and/or physical examination (even if CT/MRI is normal). 8. Any past (chronic) medical illnesses that significantly impairs patient’s functional status down to mRS 3 points or more (thus not only related to CNS pathologies and including cognitive impairment), and/or with a poor prognosis (e.g., neoplasms individually assessed to be of poor prognosis). 9. Cerebral venous sinus thrombosis (CVST). 10. Pulmonary embolism. 11. Systemic or suspected cerebral vasculitis. 12. Congenital or acquired coagulopathy presenting with: a. Prolonged aPTT above 30% of the upper limit of normal (local laboratory reference range), b. Increased INR ≥1.7 13. Severe liver disease including acute hepatic failure, cirrhosis with/or without portal hypertension. 14. Pregnancy. 15. Predicted life expectancy <3 months. 16. Participation in another clinical trial at the time of enrollment or planned inclusion in another clinical trial within less than 90 days of enrollment, provided that protocols of these trials interfere pathophysiologicaly or formally and administratively with the STROACT study. 17. Previous participation in the current clinical trial. 18. Advanced renal failure (eGFR <30 mL/min/1.73m2). 19. Active infection with SARS-CoV-2 (up to 10 days from the first positive testing with any recommended assay or from the first symptoms of infection or severe “long” COVID-19 / severe Post-COVID Neurological Syndrome)

Ez a vizsgálat jelenleg itt érhető el: Lengyelország.

  • Uniwersyteckie Centrum KliniczneGdansk, LengyelországRésztvevőt keres
  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w LodziLodz, LengyelországRésztvevőt keres
  • Kliniczny Szpital Wojewódzki nr 2 im. Św. Jadwigi Królowej w RzeszowieRzeszów, LengyelországRésztvevőt keres
  • Wojskowy Instytut Medyczny Panstwowy Instytut BadawczyWarsaw, LengyelországRésztvevőt keres
  • Dolnośląski Szpital Specjalistyczny im. T. Marciniaka - Centrum Medycyny RatunkowejWroclaw, LengyelországRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The STROACT study aims to evaluate the thromboembolic safety of intravenous thrombolysis with rtPA in patients with acute ischemic stroke on chronic DOAC treatment after neutralisation of the anticoagulant activity by administration of a specific reversal agent (antidote). PRIMARY OBJECTIVE – INTERVENTIONAL PART OF THE STROACT STUDY: a) The incidence of thrombotic events and all-cause mortality at 90 days: ischemic stroke, transient ischemic attack, myocardial infarction, deep-vein thrombosis, pulmonary embolism, arterial systemic embolism, and death. PRIMARY OBJECTIVE – OBSERVATIONAL PART OF THE STROACT STUDY: a) To assess the proportion of patients with AIS on active DOAC treatment without any intervention with excellent or good functional outcome in modified Rankin scale (mRS).

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 9.
A regiszteradat frissítve
2026. március 7.